ATE464042T1 - Verwendung von neboglamine zur behandlung von schizophrenie - Google Patents
Verwendung von neboglamine zur behandlung von schizophrenieInfo
- Publication number
- ATE464042T1 ATE464042T1 AT05747915T AT05747915T ATE464042T1 AT E464042 T1 ATE464042 T1 AT E464042T1 AT 05747915 T AT05747915 T AT 05747915T AT 05747915 T AT05747915 T AT 05747915T AT E464042 T1 ATE464042 T1 AT E464042T1
- Authority
- AT
- Austria
- Prior art keywords
- neboglamine
- treat schizophrenia
- schizophrenia
- treat
- dimethylcyclohexyl
- Prior art date
Links
- VCRGLZYPNNAVRP-JTQLQIEISA-N (4s)-4-amino-5-[(4,4-dimethylcyclohexyl)amino]-5-oxopentanoic acid Chemical compound CC1(C)CCC(NC(=O)[C@@H](N)CCC(O)=O)CC1 VCRGLZYPNNAVRP-JTQLQIEISA-N 0.000 title abstract 4
- 229950007573 neboglamine Drugs 0.000 title abstract 2
- 201000000980 schizophrenia Diseases 0.000 title abstract 2
- NTCVVGBUOCVHTI-AXDSSHIGSA-N (4s)-2-amino-4-[(4,4-dimethylcyclohexyl)amino]pentanedioic acid Chemical compound CC1(C)CCC(N[C@@H](CC(N)C(O)=O)C(O)=O)CC1 NTCVVGBUOCVHTI-AXDSSHIGSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000343A ITTO20040343A1 (it) | 2004-05-24 | 2004-05-24 | Uso di neboglamine (cr2249) come neuropsicotico e neuroprotettivo |
| PCT/EP2005/052340 WO2005115373A1 (en) | 2004-05-24 | 2005-05-23 | Use of neboglamine (cr 2249) as an antipsychotic and neuroprotective |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE464042T1 true ATE464042T1 (de) | 2010-04-15 |
Family
ID=34968609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05747915T ATE464042T1 (de) | 2004-05-24 | 2005-05-23 | Verwendung von neboglamine zur behandlung von schizophrenie |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7737180B2 (de) |
| EP (1) | EP1755583B1 (de) |
| JP (1) | JP4898666B2 (de) |
| AT (1) | ATE464042T1 (de) |
| AU (1) | AU2005247114B2 (de) |
| CA (1) | CA2567397C (de) |
| DE (1) | DE602005020618D1 (de) |
| DK (1) | DK1755583T3 (de) |
| ES (1) | ES2340399T3 (de) |
| IT (1) | ITTO20040343A1 (de) |
| PL (1) | PL1755583T3 (de) |
| PT (1) | PT1755583E (de) |
| WO (1) | WO2005115373A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITTO20050691A1 (it) | 2005-10-04 | 2007-04-05 | Rottapharm Spa | Uso di neboglamine nella terapia delle tossicodipendenze |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1931927A1 (de) * | 1968-07-06 | 1970-01-15 | Yamanouchi Pharma Co Ltd | Neue Cyclohexylaminderivate |
| IT1264765B1 (it) * | 1993-03-10 | 1996-10-04 | Rotta Research Lab | Derivati dell'acido glutammico ed acido aspartico, procedimento per la loro preparazione e loro uso come farmaci potenzianti la |
| AR037460A1 (es) | 2001-11-30 | 2004-11-10 | Smithkline Beecham Plc | Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacion |
-
2004
- 2004-05-24 IT IT000343A patent/ITTO20040343A1/it unknown
-
2005
- 2005-05-23 PT PT05747915T patent/PT1755583E/pt unknown
- 2005-05-23 DK DK05747915.6T patent/DK1755583T3/da active
- 2005-05-23 WO PCT/EP2005/052340 patent/WO2005115373A1/en not_active Ceased
- 2005-05-23 AU AU2005247114A patent/AU2005247114B2/en not_active Ceased
- 2005-05-23 PL PL05747915T patent/PL1755583T3/pl unknown
- 2005-05-23 AT AT05747915T patent/ATE464042T1/de active
- 2005-05-23 JP JP2007513918A patent/JP4898666B2/ja not_active Expired - Fee Related
- 2005-05-23 EP EP05747915A patent/EP1755583B1/de not_active Expired - Lifetime
- 2005-05-23 DE DE602005020618T patent/DE602005020618D1/de not_active Expired - Lifetime
- 2005-05-23 CA CA2567397A patent/CA2567397C/en not_active Expired - Fee Related
- 2005-05-23 US US11/569,545 patent/US7737180B2/en not_active Expired - Fee Related
- 2005-05-23 ES ES05747915T patent/ES2340399T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US7737180B2 (en) | 2010-06-15 |
| CA2567397A1 (en) | 2005-12-08 |
| PT1755583E (pt) | 2010-05-07 |
| EP1755583A1 (de) | 2007-02-28 |
| DE602005020618D1 (de) | 2010-05-27 |
| CA2567397C (en) | 2013-03-12 |
| JP2008500309A (ja) | 2008-01-10 |
| ITTO20040343A1 (it) | 2004-08-24 |
| EP1755583B1 (de) | 2010-04-14 |
| ES2340399T3 (es) | 2010-06-02 |
| PL1755583T3 (pl) | 2010-09-30 |
| AU2005247114B2 (en) | 2010-06-03 |
| US20070249715A1 (en) | 2007-10-25 |
| AU2005247114A1 (en) | 2005-12-08 |
| WO2005115373A1 (en) | 2005-12-08 |
| DK1755583T3 (da) | 2010-07-19 |
| JP4898666B2 (ja) | 2012-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE411399T1 (de) | Behandlung der huntington's krankheit mit epa | |
| ATE469674T1 (de) | 5-aminolävulinsäure-derivate zur behandlung von akne | |
| ATE373474T1 (de) | Substituierte 2-aminotetraline zur behandlung von depressionen | |
| ATE502633T1 (de) | Cyclosporins zur behandlung und vorbeugung von augenerkrankungen | |
| DE50311898D1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
| ATE390407T1 (de) | Phenethanolamin-derivate zur behandlung von atemwegserkrankungen | |
| ATE389395T1 (de) | Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson | |
| EA200601837A1 (ru) | Бензоксазины для лечения заболеваний дыхательных путей | |
| DE60312736D1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| BRPI0508051A (pt) | derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes | |
| ATE548032T1 (de) | Verwendung von chlorguanabenzderivaten zur behandlung von mit polyglutaminexpansion assoziierten erkrankungen | |
| BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
| BR0306855A (pt) | Método para o tratamento de distúrbios cognitivos | |
| EA200900269A1 (ru) | Лекарственные комбинации для лечения заболеваний дыхательных путей | |
| DE602004019778D1 (de) | Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen | |
| DE602006009556D1 (de) | Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen | |
| ATE252383T1 (de) | Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
| ATE437855T1 (de) | (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit | |
| DE60206245D1 (de) | Verwendung von r-ibuprofen methanesulfonamied und dessen salzen zur behandlung und verhinderung von abstossungreaktionen in transplartierten organen | |
| CY1110156T1 (el) | Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης | |
| EA200701615A1 (ru) | Новые лекарственные средства для лечения заболеваний дыхательных путей | |
| ATE464042T1 (de) | Verwendung von neboglamine zur behandlung von schizophrenie | |
| NO20045089L (no) | Substituerte aminoalkanfosfonsyrer for behandling av neuropatisk smerte, affektive og oppmerksomhetsforstyrrelser, schizofreni, tinnitus, myopi og andre okulaere lidelser | |
| DE69905489D1 (de) | Protein c zur behandlung von sichelzellanämie und thalassämie | |
| ATE516038T1 (de) | Metallcluster-nanoverbindungen zur behandlung von tumorerkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1755583 Country of ref document: EP |